ANIK - Anika Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.73
-0.54 (-1.98%)
As of 03:08PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close27.27
Open27.02
Bid26.73 x 800
Ask26.82 x 900
Day's Range26.04 - 27.03
52 Week Range20.12 - 32.51
Volume31,585
Avg. Volume80,973
Market Cap394.46M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-1.54
Earnings DateAug 01, 2023 - Aug 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ANIK

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone

    Hyalofast – a single-stage, off-the-shelf, resorbable, hyaluronic acid scaffold for cartilage repair – is marketed in over 35 countries outside the U.S. where it has been clinically demonstrated to be safe and effective Hyalofast has been designated as a breakthrough device by FDA, allowing prioritized interaction and review; Anika to begin filing modular PMA in 2024 with final module filing expected in 2025 Hyalofast positions Anika to lead and expand the over $350 million1 U.S. knee cartilage

  • Simply Wall St.

    With 77% ownership of the shares, Anika Therapeutics, Inc. (NASDAQ:ANIK) is heavily dominated by institutional owners

    Key Insights Institutions' substantial holdings in Anika Therapeutics implies that they have significant influence over...

  • Zacks

    Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates

    Anika (ANIK) delivered earnings and revenue surprises of -97.22% and 2.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Anika Reports First Quarter 2023 Financial Results

    Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11%BEDFORD, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2023. First Quarter 2023 Financial Summary Revenue in the first quarter of 2023 was $37.9 million, up 3% compared with $36.7 million in the first quarter o

  • Simply Wall St.

    The past five years for Anika Therapeutics (NASDAQ:ANIK) investors has not been profitable

    In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

  • GlobeNewswire

    Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023

    BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2023 financial results after the close of the market on Tuesday, May 9, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-888-886-7786 (to

  • Reuters

    UPDATE 1-Anika Therapeutics reaches settlement with activist investor Caligan

    Anika Therapeutics reached a settlement with Caligan Partners that includes adding one of the activist investor's proposed director candidates to its board. The biotechnology company, which makes osteoarthritis knee pain relief injection treatments, said on Thursday it is appointing former Johnson & Johnson executive Gary Fischetti as a director and expanding the size of the board to eight members.

  • GlobeNewswire

    Anika Enters Into Cooperation Agreement with Caligan Partners

    Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee BEDFORD, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”). As part of the agreement, the Company appointed Gary Fischetti as a Class III director. Fischetti will j

  • GlobeNewswire

    Anika to Participate in the 22nd Annual Needham Virtual Healthcare Conference

    BEDFORD, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023. Anika will host a virtual presentation with Q&A starting at 12:45pm ET. Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika’s website, www.anika.com. An arch

  • GlobeNewswire

    Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA

    Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing Anika reaches agreement to distribute the Marrow Cellution™ Bone Marrow Aspiration Needle in the U.S. and commences launch Launches enhanced Tactoset cannulas, which improve targeting and ease of use in a variety of foot and ankle procedures BEDFORD, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused o

  • Reuters

    UPDATE 1-Caligan pushes ahead with board challenge at Anika, nominates two directors

    Activist investor Caligan Partners has nominated two director candidates to Anika Therapeutics' seven member board, according to a regulatory filing on Monday, signaling plans to push ahead with a board challenge at the biotechnology company. The investment firm, which owns a roughly 4% stake and is one of Anika's 10 biggest shareholders, named former Johnson & Johnson executive Gary Fischetti and former healthcare technology executive and experienced board member James Hogan as its candidates, according to the filing.

  • Reuters

    Caligan pushes ahead with board challenge at Anika, nominates two directors

    Activist investor Caligan Partners has nominated two director candidates to Anika Therapeutics' seven member board, according to a regulatory filing on Monday, signaling plans to push ahead with a board challenge at the biotechnology company. The investment firm, which owns a roughly 4% stake and is one of Anika's 10 biggest shareholders, named former Johnson & Johnson executive Gary Fischetti and former healthcare technology executive and experienced board member James Hogan as its candidates, according to the filing.

  • GlobeNewswire

    Anika Files Preliminary Proxy Statement

    BEDFORD, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has filed its preliminary proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The meeting date has not yet been scheduled and shareholders do not need to take any action at this

  • Zacks

    Anika Therapeutics (ANIK) Stock Sinks As Market Gains: What You Should Know

    Anika Therapeutics (ANIK) closed at $26.62 in the latest trading session, marking a -0.89% move from the prior day.

  • ACCESSWIRE

    Sidoti's Small-Cap Virtual March Conference

    Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 22-23, 2023.

  • Simply Wall St.

    We Think Anika Therapeutics (NASDAQ:ANIK) Can Easily Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Simply Wall St.

    Anika Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

    Anika Therapeutics ( NASDAQ:ANIK ) Full Year 2022 Results Key Financial Results Revenue: US$156.2m (up 5.7% from FY...

  • GlobeNewswire

    Anika to Participate in the Sidoti Small Cap Virtual Investor Conference

    BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Wednesday, March 22, 2023. Anika will host a virtual presentation with Q&A starting at 9:15am ET. Webcast of the presentation and Q&A will be available in the Investor Relations section of Anika’s website, www.anika.com. An archive o

  • GlobeNewswire

    Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting

    Recently Commenced Full Market Release of X-Twist™ Fixation System, a Cornerstone Product in Anika’s Sports Medicine Portfolio RevoMotion™ Reverse Shoulder Arthroplasty System Now in Limited Market Release in U.S. OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System and Tactoset® Injectable Bone Substitute Featured at 2023 AAOS BEDFORD, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced it is h

  • Insider Monkey

    Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2022 Earnings Call Transcript

    Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2022 Earnings Call Transcript March 6, 2023 Operator: Greetings, and welcome to Anika’s Fourth Quarter and Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now […]

  • Thomson Reuters StreetEvents

    Q4 2022 Anika Therapeutics Inc Earnings Call

    Q4 2022 Anika Therapeutics Inc Earnings Call

  • Zacks

    Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

    Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • AP Finance

    Anika: Q4 Earnings Snapshot

    BEDFORD, Mass. (AP) — Anika Therapeutics Inc. (ANIK) on Monday reported a loss of $4.9 million in its fourth quarter. The Bedford, Massachusetts-based company said it had a loss of 34 cents per share. The medical technology company posted revenue of $39.6 million in the period.

  • GlobeNewswire

    Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results

    Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6% Completed First Surgeries and Initiated Limited Market Release of New RevoMotion™ Reverse Shoulder Arthroplasty System Commenced Full Market Release of X-Twist™ Fixation System in Sports Medicine Hyalofast®, Anika’s Off-the-Shelf Single-Stage Cartilage Repair Product, Designated as a Breakthrough Device by FDA; Pivotal Phase III Clinical Trial Approaching Full Enrollment, with 199 Enrolled out of 200 Engaging

  • GlobeNewswire

    Anika to Participate in the Canaccord Genuity Musculoskeletal Conference

    BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate at the Canaccord Genuity Musculoskeletal Conference in Las Vegas, NV on Tuesday, March 7, 2023 at 3:00 p.m. PT (6:00 p.m. ET). A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. An audio archive of the session will also be available